Candel Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 0.12M0.12M0.12M2.60M2.09M
Gross Profit 0.12M0.12M0.12M2.60M2.09M
Operating items
Research & Development 8.75M15.18M20.79M24.51M19.31M
Wages, Salaries and Other 7.57M6.83M
Selling, General & Administrative 5.18M10.67M14.06M13.88M14.06M
Restructuring Costs 2.65M1.96M
Other Operating Expenses -2.65M-1.96M
Operating Expenses 13.94M25.85M34.85M38.39M33.37M
Operating Income -13.81M-25.73M-34.72M-38.39M-33.37M
EBIT -13.81M-25.73M-34.72M-38.39M-33.37M
Non-operating items
Interest & Investment Income 0.11M-0.05M1.22M2.08M1.09M
Non Operating Income -3.87M-10.40M15.93M0.45M-21.81M
Net income details
EBT -13.70M-25.78M-35.21M-33.72M-30.20M
Profit After Tax -17.68M-36.12M-18.80M-37.94M-55.20M
Income from Continuing Operations -13.70M-25.78M-35.21M-33.72M-30.20M
Consolidated Net Income -13.70M-25.78M-35.21M-33.72M-30.20M
Income towards Parent Company -13.70M-25.78M-35.21M-33.72M-30.20M
Net Income towards Common Stockholders -13.70M-25.78M-35.21M-33.72M-30.20M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 24.80M28.69M28.89M28.92M32.48M
Shares Outstanding (Diluted Average) 18.87M28.82M
EBITDA -17.66M-36.12M-34.72M-38.39M-33.37M